Miller KL, Fermaglich LJ, Maynard J. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases. Orphanet J Rare Dis. 2021;9(1):265.

Krishna R, Suryawanshi S, Rascher J, Hartmann S, Sebastien B, Barrett JS. Innovations and best practices for therapeutic development in pediatric rare diseases: a model-informed drug development perspective. Clin Pharmacol Ther. 2025. https://doi.org/10.1002/cpt.3683

Wright CF, FitzPatrick DR, Firth HV. Paediatric genomics: diagnosing rare disease in children. Nat Rev Genet. 2018;19(5):253–68.

Article  CAS  PubMed  Google Scholar 

Sanders SJ, Sahin M, Hostyk J, Thurm A, Jacquemont S, Avillach P, et al. A framework for the investigation of rare genetic disorders in neuropsychiatry. Nat Med. 2019;25(10):1477–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

FDA. FDA patient-focused drug development guidance series for enhancing the incorporation of. the patient’s voice in medical product development and regulatory decision making. https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical. Accessed 18 Aug 2025.

FDA. FDA-led patient-focused drug development (PFDD). Public meetings. https://www.fda.gov/industry/prescription-drug-user-fee-amendments/fda-led-patient-focused-drug-development-pfdd-public-meetings. Accessed 18 Aug 2025

FDA. Research C for, DE and externally-led patient-focused drug development (EL-PFDD) high level overview. 2022. https://www.fda.gov/industry/prescription-drug-user-fee-amendments/externally-led-patient-focused-drug-development-meetings. Accessed 18 Aug 2025.

FDA. Developing and submitting proposed draft guidance. relating to patient experience data guidance for industry and other stakeholders. https://www.fda.gov/drugs/developing-and-submitting-proposed-draft-guidance-relating-patient-experience-data-guidance-industry. Accessed 5 Dec 2025.

FDA. Condition-specific meeting reports and other information related to patients' experience. https://www.fda.gov/industry/prescription-drug-user-fee-amendments/condition-specific-meeting-reports-and-other-information-related-patients-experience. Accessed 18 Aug 2025.

Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165–73.

Article  PubMed  Google Scholar 

van Silfhout NY, van Muilekom MM, van Karnebeek CD, Haverman L, van Eeghen AM. PROs for RARE: protocol for development of a core patient reported outcome set for individuals with genetic intellectual disability. Orphanet J Rare Dis. 2024;19(1):354.

Human Phenotype Ontology. https://hpo.jax.org/. Accessed 18 Aug 2025.

Gargano MA, Matentzoglu N, Coleman B, Addo-Lartey EB, Anagnostopoulos AV, Anderton J, et al. The human phenotype ontology in 2024: phenotypes around the world. Nucleic Acids Res. 2024;52(D1):D1333–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

ICD-11. https://icd.who.int/en/. Accessed 18 Aug 2025

Home - OMIM - (OMIM.ORG). https://www.omim.org/. Accessed 18 Aug 2025

Association for creatine deficiencies. association for creatine deficiencies. 2023. Externally led patient-focused drug development meeting for cerebral creatine deficiency syndromes (CCDS) voice of the patient report. https://creatineinfo.org/wp-content/uploads/2023/10/CCDS-VOP-report_Final.pdf. Accessed 18 Aug 2025.

Garrison SR, Siegel IJ, Takala CR, Vaithilingam SL, Yang GW, Zoghbi AW, et al. Bridging psychiatry and rare genetic diseases: a scoping review of therapeutic strategies and diagnostic delay paired with healthcare economic burden analysis. Orphanet J Rare Dis. 2025;20(1):393.

Article  PubMed  PubMed Central  Google Scholar 

Berg AT, Ludwig NN, Wojnaroski M, Chapman CAT, Hommer R, Conecker G, et al. FDA patient-focused drug development guidances. Neurology. 2024;102(1):e207958.

Article  PubMed  Google Scholar 

Ludwig NN, Wojnaroski M, Suskauer SJ, Slomine BS, Kaiser A, Paltell K, et al. Novel approaches to measuring cognition in individuals with severe to profound functional impairment: a pilot study in SCN2A-related disorder. Epilepsy Behav. 2024;160:109975.

Article  PubMed  Google Scholar 

Farmer C, Thurm A, Troy JD, Kaat AJ. Comparing ability and norm-referenced scores as clinical trial outcomes for neurodevelopmental disabilities: a simulation study. J Neurodev Disord. 2023;15(1):4.

Article  PubMed  PubMed Central  Google Scholar 

Eisengart JB, Daniel MH, Adams HR, Williams P, Kuca B, Shapiro E. Increasing precision in the measurement of change in pediatric neurodegenerative disease. Mol Genet Metab 2022;137(1–2):201–9.

FDA. Patient-Focused Drug Development. Incorporating clinical outcome assessments into endpoints for regulatory decision-making. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory. Accessed 18 Aug 2025.

Buracchio T, Campbell M, Krudys K. Assessing clinical meaningfulness in clinical trials for alzheimer’s disease: a U.S. Regulatory perspective. Alzheimers Dement Transl Res Clin Interv. 2025;11(2):e70113.

Article  Google Scholar 

Downs J, Haywood S, Ludwig NN, Wojnaroski M, Hommer R, Muzyczka K et al. Caregiver-reported meaningful change in functional domains for individuals with developmental and epileptic encephalopathy: a convergent mixed-methods design. Dev Med Child Neurol. 2025. https://doi.org/10.1111/dmcn.16363.